drugset / Trial / NCT05624099
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.
Timeline
- Start
- 2023-08-01
- Primary completion
- 2025-12-01
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Nedaplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | 150 mg/m2 | — |